Rami Manochakian/X
Apr 29, 2025, 13:57
Rami Manochakian: Zongertinib in Previously Treated HER2-Mutant NSCLC
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared an article on X:
Just published in NEJM. Results of: Beamion LUNG-1 phase 1a–1b of: Zongertinib (Oral, irreversible, HER2 TKI) in previously treated Patients with advanced HER2-mutant non-small- cell Lung Cancer (NSCLC).
“Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer”
Authors: John V. Heymach et al.
Behbood Sadrolhefazi
Byoung Chul Cho
cancer
David Planchard
Egbert F. Smit
Ernest Nadal
Gerrina Ruiter
Hai-Yan Tu
John V. Heymach
Jon Zugazagoitia
Joshua K. Sabari
Kiyotaka Yoh
Maren Rohrbacher
Myung-Ju Ahn
NEJM
Nicolas Girard
Noboru Yamamoto
NSCLC
OncoDaily
Oncology
Sabina Eigenbrod-Giese
Ute von Wangenheim
Yanqiu Zhao
Yi-Long Wu
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 9, 2025, 12:42
May 9, 2025, 12:26
May 9, 2025, 11:53